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ABSTRACT
We tested the clinical utility of combined profiling of Ion Torrent PGM based 
next-generation sequencing (NGS) and immunohistochemistry (IHC) for assignment 
to molecularly targeted therapies. A consecutive cohort of 93 patients with advanced/
metastatic GC who underwent palliative chemotherapy between March and December 
2015 were prospectively enrolled. Formalin fixed paraffin embedded tumor biopsy 
specimens were subjected to a 10 GC panels [Epstein Barr virus encoding RNA  
in-situ hybridization, IHC for mismatch repair proteins (MMR; MLH1, PMS2, MSH2, and 
MSH6), receptor tyrosine kinases (HER2, EGFR, and MET), PTEN, and p53 protein], and 
a commercial targeted NGS panel of 52 genes (Oncomine Focus Assay). Treatment 
was based on availability of targeted agents at the time of molecular diagnosis. 
Among the 81 cases with available tumor samples, complete NGS and IHC profiles 
were successfully achieved in 66 cases (81.5%); only IHC results were available for 
15 cases. Eight cases received matched therapy based on sequencing results; ERBB2 
amplification, trastuzumab (n = 4); PIK3CA mutation, Akt inhibitor (n = 2); and FGFR2 
amplification, FGFR2b inhibitor (n = 2). Eleven cases received matched therapy based 
on IHC; ERBB2 positivity, trastuzumab (n = 5); PTEN loss (n = 2), PI3Kβ inhibitor; MMR 
deficiency (n = 2), PD-1 inhibitor; and EGFR positivity (n = 2), pan-ERBB inhibitor. A 
total of 19 (23.5%) and 62 (76.5%) cases were treated with matched and non-matched 
therapy, respectively. Matched therapy had significantly higher overall response rate 
than non-matched therapy (55.6% vs 13.1%, P = 0.001). NGS and IHC markers provide 
complementary utility in identifying patients who may benefit from targeted therapies.
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INTRODUCTION
Despite combined treatment with surgical resection 
and adjuvant chemotherapy, 25–40% of patients with stage 
II-IV Gastric cancer (GC) experience relapse [1, 2].  Large-
scale molecular profiling of GC, as reported in The Cancer 
Genome Atlas (TCGA) and Asian Cancer Research Group 
(ACRG), identified multiple cancer drivers as potential 
therapeutic targets [3, 4]. However, chemotherapy remains 
the only treatment option for patients diagnosed with 
advanced GCs with dismal outcome, with the exception 
of trastuzumab for a HER2-positive GC subset, based on 
the results of the TOGA trial [5].
Advances in genome sequencing technology have 
allowed the identification of potential therapeutic targets 
using formalin fixed paraffin embedded (FFPE) tumor 
biopsy specimens within a timeframe compatible with 
clinical practice [6]. Using a genome forward designs, 
clinical trials have been conducted to investigate the efficacy 
of targeted agents against specific molecular aberrations 
in a single or multiple tumor types [7–11]. Findings from 
histology-agonistic approaches demonstrated improved 
progression free survival (PFS) and overall survival (OS) 
compared to those achieved with non-matched therapy 
[11, 12]. However, in randomized trial with heavily treated 
solid tumors, targeted agents did not improve the PFS over 
physician’s choice [9]. As a histology-dependent approach, 
BATTLE and SAFIRO01 trials established the feasibility 
of a genome forward approach in lung and breast cancer 
patients [7, 13].
Regarding GC, despite recent studies with 
comprehensive molecular profiling [3, 4, 14, 15], no clinical 
data demonstrating target-drug efficacy in the context of 
umbrella studies have been published yet. In addition, 
the very small sizes of FFPE gastric biopsy specimens 
pose practical and technical challenges often result in 
sequencing assay failures due to low yield and poor quality 
of extracted DNA. Therefore, we combined Ion Torrent 
PGM based amplicon sequencing (Oncomine Focus Assay, 
Thermo Fisher Scientific, Waltham, MA, USA) with an 
immunohistochemistry (IHC) panel to maximize the chance 
of assignment of enrolled patients to potentially beneficial 
targeted therapies. We also aimed to assess whether our 
genome forward umbrella approach could improve patient 
outcomes when compared to non-matched, standard 
chemotherapy for advanced/metastatic GC.
RESULTS
Patients and molecular aberrations 
Sample set and clinicopathologic characteristics 
Among the total 81 patients, 50 (61.7%) were male 
with the median age of 57 years (range 28–76). Biopsy 
samples (50 endoscopic biopsies and 8 excisional biopsies 
for metastatic sites) were used for two-thirds of cases 
(n = 58, 71.6%). Nineteen patients (23.5%) were treated 
with matched therapy and 62 (76.5%) were treated with 
non-matched therapy (Table 1).
Molecular profiling: mutation, amplification, and 
overexpression
For all 81 cases, we profiled 10 molecular markers 
using IHC and in situ hybridization (ISH). From a 
combination of markers, we observed a median of 1 
genomic aberration per case (range 0–4). Of those, 
Epstein-Barr virus (EBV) was identified by ISH in 3 
(3.7%) case, and 2 of those harbored the PIK3CA Q546K 
mutation upon NGS. Mismatch repair (MMR) deficiency 
was demonstrated in 5 (6.2%) cases, all of which exhibited 
simultaneous losses of MLH1 and PMS2 expression. 
Receptor tyrosine kinase (RTK) overexpression occurred 
in 46 (56.8%) cases, when scores of 2+ and 3+ were 
defined as positive expression. [16]  PTEN loss was 
observed in 15 patients (18.5%). 
Complete NGS and IHC profiles were available for 
66 cases (81.5%). At least 1 mutation or amplification 
was found in 30 (45.5%), of which 26 (86.7%) harbored 
single aberrations and 4 (13.3%) had multiple aberrations 
(Figure 1). The most common mutations were as follows; 
PIK3CA (n = 6, 9.1%) TP53 [n = 4, 40% among 10 cases 
with Oncomine Comprehensive Assay (OCA)], and KRAS 
(n = 3, 4.5%). All PIK3CA mutations, including Q546K 
(n = 3), K111E (n = 1), R93Q (n = 1), H1047R (n = 1), 
V344M (n = 1), and 3 were co-occurrence mutations with 
KRAS (G12D), PIK3CA (E726K), and ERBB3 (V104M). 
Non-V600E BRAF mutation (D594E) was detected in 1 case. 
Amplification was detected in 17 cases (25.8%) 
and was mutually exclusive with mutation. Among 
those, 16 cases (94.1%) exhibiting amplification on 
NGS also exhibited gene amplification on SISH or FISH 
assay (Appendix Table 2 and Figure 2A–2E). One case 
exhibited ERBB2 amplification on NGS but neither 
SISH amplification nor HER2 expression RTK (#32 in 
Figure 1). Among the 10 cases that exhibited receptor 
tyrosine kinase (RTK) overexpression via IHC (3+) in the 
absence of corresponding gene amplification (Appendix 
Table 3), 5 cases exhibited ERBB2 (n = 2), MET (n = 2), 
or EGFR (n = 1) amplification by SISH concordant with 
the IHC results (Appendix Figure 2F–2G, red arrows 
in Figure 1). However, the other 5 cases did not exhibit 
gene amplification in agreement with the NGS results 
(Appendix Figure 2H–2I, blue arrows in Figure 1). 
Treatment assignment and clinical outcomes
Patients with or without molecular aberrations
Of the 30 cases with NGS-detected genetic 
aberrations, 9 were treated with matched therapy and 21 
were treated with non-matched therapy (Figure 2). Among 
those matched therapy, ERBB2 amplification (n = 4) 
were treated with trastuzumab-containing chemotherapy 
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(trastuzumab, capecitabine, and cisplatin), and PIK3CA 
mutation (n = 2) were treated with oral Akt inhibitor, 
afuresertib in combined with paclitaxel (ClinicalTrials.
gov Identifier: NCT02240212). FGFR2 amplification 
(n = 2) were treated with FPA144 monotherapy, antibody 
to FGFR2b receptor, (ClinicalTrials.gov Identifier: 
NCT02318329), and PTEN loss (n = 1) received 
matched therapy with GSK2636771, PI3Kβ inhibitor in 
combined with paclitaxel (ClinicalTrials.gov Identifier: 
NCT02615730).
For the 51 remaining cases, 10 were treated with  matched 
therapy according to the IHC results; trastuzumab containing 
chemotherapy for ERBB2 positivity (3+, n = 5), PI3Kβ 
inhibitor for PTEN loss (n = 1), pan-ERBB tyrosine kinase 
inhibitor, afatinib with paclitaxel (ClinicalTrials.gov Identifier: 
NCT02501603) for EGFR positivity (n = 2), and pembrolizumab-
Table 1: Clinicopathological characteristics 
Characteristics No. % Matched (%) Non-matched (%) P 
Total  81 19 (23.5%) 62 (76.5%)
Age, years
  Median (range) 57 (28–76) 59 (29–73) 57 (28–76) 0.95
Gender
  Male 50 61.7 12 (63.2%) 38 (61.3%) 0.88
  Female 31 38.3 7 (36.8%) 24 (38.7%)
Differentiation
  Well 1 1.2 1 (5.3%) 0 0.20
  Moderate 24 29.6 8 (42.1%) 16 (25.8%)
  Poorly 38 46.9 7 (36.8%) 31 (50.0%)
  Signet ring cell 16 19.8 3 (15.8%) 13 (21.0%)
  Others 2 2.5 0 2 (3.2%)
Tumor location 
  Upper 8 9.9 1 (5.3%) 7 (11.3%) 0.87
  Body 27 33.3 6 (31.6%) 21 (33.9%)
  Antrum 38 46.9 10 (52.6%) 28 (45.2%)
  Entire 8 9.9 2 (10.5%) 6 (9.7%)
Tissue samples
  Gastrectomy 23 28.4 2 (10.5%) 21 (33.9%) 0.14
  Endoscopic biopsy 50 61.7 15 (78.9%) 35 (56.5%)
Biopsy for 
metastatic sites 8 9.9 2 (10.5%) 6 (9.7%)
Stage at diagnosis
  I 3 3.7 1 (5.3%) 2 (3.2%) 0.55
  II 7 8.6 1 (5.3%) 6 (9.7%)
  III 11 13.6 1 (5.3%) 10 (16.1%)
  IV 60 74.1 16 (84.2%) 44 (71.0%)
Metastatic site
  Peritoneum 45 55.6 9 (47.4%) 36 (58.1%) 0.41
  Lymph node 26 32.1 9 (47.4%)  17 (27.4%) 0.06
  Liver 23 28.4 9 (47.4%) 14 (22.6%) 0.05
  Lung 5 6.2 2 (10.5%) 3 (4.8%) 0.37
  Bone 2 2.5 1 (5.3%) 2 (3.2%) 0.87
Prior therapies 
 Treatment naive 33 40.7 9 (47.4%) 24 (38.7%) 0.50
 1–2 48 59.3 10 (52.6%) 38 (61.3%)
Oncotarget38392www.impactjournals.com/oncotarget
containing regimen, a monoclonal antibody to programmed cell 
death 1 (PD-1) inhibitor for MMR-deficiency (n = 2). 
Responses and survival 
Of the 79 evaluable patients, 18 patients (22.8%) 
had confirmed partial responses (cPR) and 50 (63.3%) 
had stable diseases (Appendix Table 4). Patients who 
received matched therapy had a higher overall response 
rate (ORR) of 55.6%, compared with 13.1% for those 
treated with non-matched therapy (Figure 3A, P = 0.001). 
With median 19.6 months of follow-up, the median PFS 
were 7.1 months for matched therapy [95% confidence 
interval (CI), 3.0–11.2], 4.6 months for non-matched 
ramucirumab/paclitaxel group (95% CI, 3.8–5.4), and 6.9 
months for non-matched chemotherapy group (95% CI, 
4.8–9.0), respectively (P = 0.033, Figure 3B). The median 
PFS was slightly longer for matched group compared to 
non-matched group (7.1 vs 5.2 months, P = 0.07). 
Clinical response to matched therapy
Two patients with PIK3CA Q546K mutation were 
enrolled in a phase IB clinical trial with Akt inhibitor. 
The first GC patient (Case #3 in Figure 1) presented 
with hepatic metastases was treated with 200 mg of daily 
afuresertib combined with weekly paclitaxel as second line 
treatment. A computed tomography (CT) scan at the end of 
Figure 1: Mutation, amplification, and protein expression profiles. Vertical lines indicate gene names; horizontal lines indicate 
the cases. Red and blue arrows indicate cases with concordant IHC and NGS, respectively. Empty squares indicate false-positive ERBB2 
amplification on NGS. Squares with diagonal lines indicate false-negative RTK amplification on NGS. Asterisks denote representative 
cases treated with matched therapy.
Figure 2: CONSORT diagram. T: paclitaxel, X: capecitabine, C: cisplatin. 
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cycle 3 (12 weeks) showed cPR to treatment with a 41.8 % 
reduction (Figure 4A). The patient was removed from the 
study with a time to progression of 25 weeks. Second case 
(Case #1 in Figure 1) was 67-year-old male with paraaortic 
and hepatic metastases. He was treated with afuresertib 
and paclitaxel. A CT scan at 16 weeks demonstrated cPR 
with a 37.7% tumor reduction (Figure 4B), and he remains 
on treatment after 17 weeks.
The third case (Case #10 in Figure 1) developed 
multiple hepatic recurrences 7 months after curative 
resection (initially stage IB). The tumor was PTEN loss 
(with H-score 60 out of 300) and he was treated with 
300 mg of daily GSK2636771 in combined with weekly 
paclitaxel. A CT scan at 12 weeks demonstrated stable 
disease with a 24% tumor reduction (Figure 5A) and he 
remains on treatment after 25 weeks. 
A 53-year-old female patient with a MMR 
deficiency (Case #68 in Figure 1) was also treated with 
the PD-1 inhibitor, pembrolizumab (200 mg) every 
3 weeks combination with TS-1 monotherapy (50 mg bid, 
days 1–14). A CT scan at 12 weeks indicated cPR with a 
49.8% tumor reduction; she is on treatment after 34 weeks 
(Figure 5B).
DISCUSSION
In recognition of inter-patient molecular tumor 
heterogeneity, NGS-based basket trials with specific 
molecular aberrations across multiple tumor types were 
widely studied [9–11]. However, in SHIVA trial, the off-
label use of molecularly targeted agents did not improve 
PFS in heavily pretreated cancer patients when compared 
with physician’s choice [9]. As demonstrated by the 
different efficacy of BRAF inhibitors in melanoma and 
colon cancer [17], the inclusion of multiple tumor types 
with the same molecular target in a basket trial might 
introduce an important source of heterogeneity and could 
lead to negative results.
These observations justify a shift toward a 
histology dependent approach involving targeted agents. 
The BATTLE study demonstrated the feasibility and 
utility of umbrella approach for advanced non-small cell 
lung cancer (NSCLC) [13]. TCGA classified GCs into 
four molecular subtypes; EBV-positive tumors (8.8%), 
microsatellite instability-high (MSI-H) tumors (21.6%), 
genomically stable tumors (GS, 19.6%), and tumors with 
chromosomal instability (CIN, 49.6%) [3]. In our study, 
combination of OFA and IHC panels covered most of the 
key druggable targets for each subgroup. Our pilot study 
results demonstrated that the matched group experienced 
significantly better responses and survival and provides 
justifying the need for further umbrella trials in GC. We 
await the results of two ongoing umbrella trials PANGEA 
and VIKTORY We await the results of 3 ongoing umbrella 
trials for GC(ClinicalTrials.gov Identifier: NCT02213289, 
NCT02299648 and NCT02951091). (ClinicalTrials.gov 
Identifier: NCT02213289 and NCT02299648). 
Genomic profiling of biopsied metastatic lesions 
often presents practical challenges because of the small 
quantities of available samples. The OCA, which is based 
on Ion Torrent PGM amplicon sequencing platform 
is currently used as a screening platform for the NCI 
Figure 3: Efficacy data based on molecular profiling (A) Waterfall plot of all patients demonstrating the maximum percent 
change with respect to baseline. Progression-free survival (B) and overall survival (C). T; trastuzumab, P; pembrolizumab, A; Akt 
inhibitor, B; PI3Kβ inhibitor, E; pan-ERBB inhibitor.
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MATCH study because of its low sample requirement 
(20 ng DNA and 10ng RNA from FFPE specimens), and 
ability to detect CNAs and gene fusions as well as SNVs. 
The OFA is a subset of OCA that mainly targets actionable 
cancer drivers. The success rate of our genomic analyses 
(71%, 66 /93) was similar to those reported trials that used 
large-scale genomic analyses, with main reason of failure 
being low cellularity and DNA contents [7, 9, 12].
Despite the known difficulty of reliable CNA 
detection from amplicon-based targeted sequencing 
data (because of variable amplification efficiency across 
targets) [14, 18], OFA with a proprietary analysis pipeline 
Figure 4: Representative clinical responses of 2 PIK3CA mutant cases in the matched group that were treated with 
the combination of an Akt inhibitor and paclitaxel. CT images of case #3 during the treatment course. The initial liver metastasis 
(A1) exhibited a significant size reduction (A2) after 12 weeks. (A3) PIK3CA exon 9 Q546K mutation was detected by pyrosequencing. CT 
images of case #1 at the time of baseline (B1) and at 16 weeks (B2). CT: computed tomography. 
Figure 5: Representative clinical responses in the matched group. CT images of case #10 at baseline (A1) and 12 weeks (A2) 
after treatment with a PI3Kβ inhibitor and paclitaxel. (B) CT images of case #68 at baseline and 12 weeks (B2) after pembrolizumab 
treatment. Immunohistochemistry images indicating PTEN loss in case #10 (A3) and MMR deficiency in #68 (B3).
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with in silico reference normal tissue data could identify 
17 CNAs, 16 (94.1%) of which were validated by ISH. 
However, the IHC panel was able to identify an additional 
5 ERBB2 amplified cases, which were confirmed by ISH. 
OFA alone would have missed 23% of the CNAs. On the 
other hand, the additional 5 candidate CNAs identified 
by the IHC panel (no NGS amplification, 3+ RTK 
overexpression by the IHC panel) were not detected by 
ISH or NGS. Overall, more than a half (n = 11) of the 
decisions regarding matched therapy were made based on 
IHC, underscoring the importance of combining NGS with 
an IHC panel. By applying a more sophisticated approach 
that incorporated both IHC and NGS, our cancer profiling 
led to the use of matching therapy in a greater proportion 
of cases (23.5%), as well as a higher ORR than with 
previous studies [7, 9].
There are some important issues must be 
considered when interpreting of this study.  First, this 
was not a randomized study, and therefore results must 
be interpreted cautiously. However, PFS of the non-
matched (control) group in our study was consistent with 
those reported in phase III randomized trials in support 
of our results; for example, our study showed a PFS of 
4.6 months in the non-matched ramucirumab/paclitaxel 
group, compared with 4.4 months in the ramucirumab/
paclitaxel group from the RAINBOW trial [19]. Second, 
approximately 40% cases receiving matched therapy is 
ERBB2 amplified cases, which is already been identified 
as a standard biomarker of advanced GC. However, we 
believe that the inclusion of ERBB2 amplified cases in 
our analyses is justified as the primary purpose of the 
umbrella approach is the identification of all therapeutic 
targets at the time of diagnosis, thus avoiding the need 
to successively evaluate single markers over time. 
Accordingly, ERBB2 positivity, a main genetic aberration 
of GC, should be included in this type of study. In 
support of our approach, two-thirds of matched group 
was treated according to clinical practice in the NEXT-1 
trial [18], and EGFR-mutant NSCLCs were also included 
in the analyses of the BATTLE and CUSTOM trials [10, 
13]. Interestingly, one case (case #25) has co-occurrence 
of EBV positivity and FGFR2 amplification. Tumor 
was not responded to FGFR2 inhibitor and efficacy of 
immune checkpoint inhibitor needs to be determined. 
Finally, the algorithms used to interpret genomic data 
and assign targeted therapies need to be improved in the 
era of immunotherapy and DNA repair modulation.
In this study, we have demonstrated that a 
combined NGS and IHC analysis of FFPE samples is 
a feasible method for the identification of targetable 
genomic alterations in patients with metastatic GC. In 
addition, identification of specific molecular aberrations 
and assignment of targeted therapy were associated 
with better responses and survival supportive for future 
randomized trial.
MATERIALS AND METHODS
Study design and subjects
This study had the following objectives: (1) to test 
the feasibility of NGS based genomic profiling of small 
FFPE tumor biopsies routinely produced for diagnostic 
purpose, in a time frame feasible for clinical practice; (2) 
to assign patients to matched therapy based on genomic 
aberrations; and (3) to explore the potential clinical 
benefit of a genome-forward approach over conventional 
chemotherapy.
The study scheme is outline in Appendix Figure 1. 
A consecutive cohort of 93 patients with advanced/
metastatic GC who underwent palliative chemotherapy 
at Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea between March 2015 and 
December 2015 was enrolled in this study. Of those, 12 
were excluded from genomic analysis [insufficient tumor 
cellularity, 11 patients (11.8%); lost to follow-up, 1 patient 
(1.0%)]. Among the remaining 81 patients, complete NGS 
and IHC profile were successfully obtained for 66 cases 
(81.5%). For the remaining 15 cases (18.5%), only IHC 
data were available because of failed quality control for 
the NGS analyses (insufficient DNA yield, 8 patients; poor 
DNA quality, 7 patients). The study was approved by the 
institutional review board (IRB. 4–2014-0349).
Biomarker methodology
Nucleic acid extraction from FFPE
Ten 4-mm-thick FFPE sections were used for the 
IHC panel and 2–4 sections were used for NGS. Using 
hematoxylin and eosin (H&E)-stained sections for guidance, 
tumor rich areas were reviewed and macrodissected by two 
experienced pathologists (H.K. and S.J.S) to achieve a final 
tumor content per sample over 10%. DNA was isolated 
using the Ambion RecoverAll™ Multi-sample DNA 
workflow (Thermo Fisher Scientific, Waltham, MA, USA) 
according to the manufacturer’s instructions. DNA was 
quantified using the Qubit 2.0 fluorometer High sensitivity 
kit (Thermo Fisher Scientific).
Library construction and sequencing
Ten to twenty nanograms of DNA were amplified 
using Oncomine Comprehensive Assay (OCA, case #1–10 
in Figure 1) or Oncomine Focus Assay (OFA, case 11–66) 
DNA panels targeting 143 and 52 genes, respectively, 
according to manufacturer’s instruction (Appendix Table 1). 
RNA analysis for fusion transcript was not performed, 
given the lack of clinically important fusion events in GC. 
Data analysis
Sequenced data were initially aligned and mapped 
to the human hg19 reference genome using the Torrent 
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Suite Server (ver 4.4) with default parameters. Amplicon 
coverage summary files were generated results using the 
Coverage Analysis plug-in (version 4.4.12–1). The Ion 
Reporter Workflow (version 5.0) was used to perform 
variant calling of the DNA libraries. In detail, gene 
annotation was performed using the Oncomine Panel 
v1.1 Annotations set and copy number baseline was 
performed using the Oncomine Panel v2.0. Baseline and 
Oncomine Variant annotator v2.0 plugin was used for 
analysis. Analyzed variants were re-categorized using 
the Oncomine knowledgebase, which includes currently 
approved drugs and clinical trials. We used the following 
cutoff values: coverage, > 1000×; and proportion of reads 
on target, > 80%.
Immunohistochemical staining, epstein–barr virus-
encoded small RNA-In Situ hybridization, and evaluation
IHC was performed on a Ventana XT automated 
staining instrument (Ventana Medical Systems, Tucson, 
AZ, USA). The following target-specific antibodies were 
used according to the manufacturer’s instructions and a 
previous study [20]: MutL homolog 1 (MLH1, ready to 
use, clone M1, Roche, Basel, Switzerland), MutS protein 
homolog 2 (MSH2, ready to use, clone G219-1129, Roche), 
MutS homolog 6 (MSH6, 1:100, clone 44, Cell Marque, 
Rocklin, CA, USA), postmeiotic segregation increased 
2 (PMS2, 1:40, clone MRQ28, Cell Marque), ERBB2 
(ready to use, clone 4B5, Roche), EGFR (1:100, EP38Y, 
Abcam, Cambridge, UK), c-MET (ready to use, clone 
SP44, Roche), PTEN (1:100, clone 138G6, Cell Signaling, 
Danvers, MA, USA), and p53 (1:300, DO7, Novocastra, 
Newcastle, UK). Epstein-Barr virus-encoded small RNAs 
(EBER) in situ hybridization (ISH) was performed using 
a Ventana Benchmark ISH system and ISH iView kit 
(Ventana Medical Systems, Tucson, AZ, USA). 
In situ hybridization for amplification
Gene amplifications identified via OCA and OFA 
were confirmed using silver ISH (SISH) and fluorescence 
ISH (FISH). Gene amplification was defined as > 6 gene 
copies per nucleus or a gene signal/centromere signal 
ratio > 2.0 according to previous study. [21–27] Probes 
recognizing the following targets were used: HER2 
(INFORM® HER2 DNA and Chr 17 SISH probes, Roche), 
EGFR (INFORM® EGFR DNA and Chr 7 SISH probes, 
Roche), MET (INFORM® MET DNA and Chr 7 SISH 
probes, Roche), FGFR2 (FGFR2/CEN10p FISH probe; 
Abnona Corporation, Taipei, Taiwan), C-myc (MYC DNP 
and Chr 8 probe, Roche), and CCND1 (CCND1/CEP11 
FISH probe, Vysis, Downers Grove, IL, USA). 
Therapy
Assignment to a matched therapy was determined 
after reviewing the clinical, laboratory, and pathologic 
data from all available patient records. Patients whose 
tumors harbored molecular aberrations were preferably 
considered for clinical trials with a matched therapy, 
when available with the following prioritization criteria. 
(1) Actionable molecular aberrations, wherein any 
mutation, deletion, or amplification was deemed to be of 
greater importance; in case with no aberrations, loss of 
protein of IHC expression was selected. (2) The allocation 
of patients to investigational treatment varied over time 
according to the availability of ongoing clinical trials, and 
off-label treatment, as well as the patient’s or physician’s 
preference.
Statistical analysis
The χ2 test was used to assess the correlation 
between marker status and clinical significance. All the 
tests were 2-sided, and P values of < 0.05 were considered 
significant. Responses were assessed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria version 1.1 [28]. PFS was defined from the first 
day of treatment to the time of disease progression or 
death. OS was measured from the time of surgery to 
death or the last follow-up date and evaluated by survival 
analysis using the Kaplan-Meier method with a log-rank 
test. All statistical analyses were performed using SPSS 
version 18.0 (IBM, Chicago, IL, USA).
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